

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912

CLARIFICATION/REPLY



10 September 2019

To
Avishkar Naik
Vice President
National Stock Exchange
Surveillance

Reference: Your email dated 9th September, 2019 with reference number NSE/CM/Surveillance/8534

Subject: Reply to the Clarification on Price sensitive information and intimation on Compliance under Regulation 30 of SEBI (Listing Obligations and Disclosure) (LODR), 2015

Dear Sir,

With respect to the Quoted subject, we hereby clarify you that the Company has duly informed the exchange on all material disclosures that is obligated to give under SEBI (LODR), 2015 and especially with respect to Regulation 30.

The latest information given to Stock exchanges under Regulation 30 is with respect to


Date	Announcement/Information
02-08-2019	Revocation of Stop Production order
09-08-2019	Resignation and Appointment of Company Secretary / Compliance Officer

Other than the above Announcement/Information, the Company has informed the exchanges regards Outcome of Board meeting, Quarterly Financials, AGM Notice, Annual Report, Book closure dates under various Regulations of SEBI (LODR), 2015. The Company has not suppressed any information which ought to be disclosed by law and neither has the intention to hide any materialistic information which may be treated as Price sensitive information.

The significant Price Changes/movements that have occurred and observed by you, have no bearing on the non-disclosure of any major information as enunciated in your email. The same might have occurred due to the general market movement which the Company does not have any control on.

For Krebs Biochemicals and Industries Limited


Taruni Banda



Company Secretary